tide news client reporter Liu yuan letter

To say that the most popular concept in the-share market before the long holiday is actually not the Asian Games concept stock, but the concept of weight loss. The fire lasted a month.

the weight loss concept sector index rose 13.89 percent in September, the largest increase in Shanghai and Shenzhen.

Changshan Pharmaceutical (300255.SZ), the total leader of the plate, has increased by more than 260 per cent in the past 14 trading days, making it a well-deserved leader in the concept of weight-loss drugs. However, the company said it did not have diet pills, to the market poured a pot of cold water.

Diet drug leader becomes the most valuable company in Europe

In recent months, "weight loss medicine" has been popular in domestic and foreign capital markets.

This "magic drug" is called semaglutide. It is the main active ingredient of the hypoglycemic drug Ozempic and the weight loss drug Wegovy developed by Danish pharmaceutical giant Novo Nordisk. It is a GLP-1 (glucagon-like state -1) receptor agonist.

It is understood that the weight loss principle of this "magic medicine" is to stimulate insulin secretion and inhibit glucagon secretion, thereby delaying gastric emptying and reducing appetite, and ultimately achieving the effect of reducing blood sugar and weight loss.

Novo Nordisk (NVO.US) has also been sought after in the capital market. Its US stock price has been rising since October last year, with the largest increase of more than 50% during the year. Novo Nordisk's total market value once crossed 420 billion US dollars at its peak in September, surpassing LV's parent company to become the company with the highest market value in Europe. Another industry leader, Lilly (LLY.US), rose nearly 70% for the year.

the reason why Novo Nordisk and Lilly are trending so well is that GLP-1 weight-loss drugs represented by Simaglutide continue to be popular. overseas investment banks have recently raised their sales forecasts for weight-loss drugs. it is estimated that the annual sales of GLP-1 agonist drugs will exceed us $100 billion in 2030.

According to Lilly's latest quarterly report, Lilly's dual-target (GLP-1R/GIPR) weight-loss drug, Tilpotide, shocked the market and became the fastest drug in history. Tilpopeptide sold a total of US $1.55 billion in the first half of the year, reaching US $0.98 billion in the second quarter alone, up 72% quarter-on-quarter. Lilly even further raised Tilpopeptide's full-year sales forecast to US $4 billion.

A-share diet drug leader has no diet drug products

At a time when Novo Nordisk's share price is reaching new highs, the concept of weight loss is becoming more and more popular in A- shares.

Changshan Pharmaceuticals has gained more than 260 per cent in the past 14 trading days.

from the opening price of 4.47 yuan on September 11 to the closing price of 13.38 yuan on September 28, the cumulative increase has also reached an astonishing 200. Changshan Pharmaceutical has also become a well-deserved weight-loss drug concept stock leader.

others, such as borui medicine (688166.SH), have also seen a sharp rise recently, with a cumulative increase of 60% in September.

the weight loss concept sector index rose 13.89 percent in September, the largest increase in Shanghai and Shenzhen.

Ironically, so far, Changshan Pharmaceutical does not have any weight loss products.

it is understood that the active funds in the market are targeting Changshan pharmaceutical's original 1.1 innovative drug albenatide, which belongs to the GLP-1 long-acting preparation together with semaglutide, the "magic drug for weight loss" that has attracted the attention of the capital market.

However, Changshan Pharmaceutical's currently approved clinical indication for the treatment of type 2 diabetes. In addition, Changshan Pharmaceutical has started clinical trials of the drug since 2013 and has not yet applied for listing.

Changshan Pharmaceutical pointed out in its announcement on the evening of September 25 that the clinical trial of albenatide carried out by the company is indicated for the treatment of type 2 diabetes and does not involve obesity indications. The Company has not conducted clinical trials of exbenatide for obesity or weight loss. The company does not cover revenue from weight loss efficacy products.

according to the data of the dragon and tiger list of the exchange, institutions do not have much participation in weight loss concept stocks, while several business departments of Oriental Wealth, known as the retail stronghold, are the most active in the trading of Changshan Pharmaceutical. Guotai Junan Nanjing Taiping South Road, Caitong Securities Wenling Zhonghua Road and other hot money are also extremely active.

Huadong Medicine's "Diet Medicine" has been approved for listing

On the evening of September 14, Huadong Medicine (0009633.SZ) disclosed an announcement stating that the company's application for a new drug clinical trial (IND) of oral small molecule GLP-1 receptor agonist HDM1002 tablets for weight management indications for overweight or obese people was recently obtained. Approved by the State Drug Administration.

The announcement shows that HDM1002 Tablets is a new class 1 chemical drug independently developed by East China Medicine and has global intellectual property rights. It is an orally active, potent, and highly selective GLP-1 receptor small molecule full agonist. It is reported that the product's type 2 diabetes IND was approved by China's NMPA and the US FDA in May.

Up to now, there are no oral small molecule GLP-1 receptor agonist drugs on the market in the world. It is understood that Pfizer, Lilly and other global head pharmaceutical companies are also developing oral small molecule GLP-1 drugs.

Preclinical studies of Huadong Medical HDM1002 have shown that as an oral small molecule GLP-1 receptor agonist, it can strongly activate the GLP-1 receptor and induce the production of cyclic adenosine monophosphate (cAMP), which has a strong effect on improving glucose tolerance, lowering blood sugar and weight loss, and shows good safety.

before that, the diabetes indication and obesity or overweight indication (lilupin) of liraglutide injection of east China medicine were approved for listing in March and June this year respectively. east China medicine became the first enterprise in China to submit and successfully approved the registration application for two indications of liraglutide biosim.

Photo Source: Jingdong Pharmacy

the announcement of investor relations records disclosed by East China Medicine on August 16 shows that the indications for diabetes of liraglutide injection are being listed and admitted to hospitals in all provinces of the country, and the work of listing has been completed in more than 20 provinces across the country, and the listing of all provinces is expected to be completed in September. Up to now, it has achieved admission sales in hundreds of hospitals, and the number is still growing rapidly. In addition, the out-of-hospital market is also the main sales channel for weight loss indications, including online platforms and offline pharmacies, medical and beauty institutions, East China Medicine is also actively layout. Offline pharmacies are expected to achieve coverage of more than 30000 chain retail pharmacies in the third quarter of this year.

According to reports, in the field of endocrinology, Huadong Medicine has built a world-leading innovative diabetes drug research and development platform with GLP-1 targets as the core. At present, the company has established 8 products covering oral, injectable and other dosage forms, including long-acting and multi-target global innovative drugs and biosities combined with GLP-1 and related targets.

"Reprint please indicate the source"